ADAMTS15抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-3: 293T, MCF-7, PC-3 cell lysates, Primary antibody: P04542(ADAMTS15 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P04542(ADAMTS15 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of ADAMTS15 Antibody**

ADAMTS15 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 15) is a member of the ADAMTS family of secreted metalloproteinases, which play critical roles in extracellular matrix (ECM) remodeling, cell adhesion, and proteolytic processing of bioactive molecules. Structurally, ADAMTS15 contains a prodomain, metalloproteinase domain, disintegrin-like module, thrombospondin type-1 (TSP1) motifs, and a cysteine-rich region, enabling interactions with ECM components and cellular signaling pathways.

Functionally, ADAMTS15 is implicated in tissue development, inflammation, and cancer. Studies suggest its involvement in tumor progression through ECM degradation, modulation of angiogenesis, or direct cleavage of signaling molecules. In certain cancers (e.g., colorectal, breast), ADAMTS15 exhibits dual roles—acting as a tumor suppressor by inhibiting proliferation or as a promoter by facilitating metastasis. Its expression is often dysregulated in pathological conditions, correlating with patient prognosis.

ADAMTS15 antibodies are essential tools for detecting and characterizing the protein in research. They enable applications such as Western blotting, immunohistochemistry, and ELISA to study its expression patterns, localization, and interactions in tissues or cell models. Additionally, these antibodies aid in exploring ADAMTS15’s therapeutic potential, including its use as a biomarker or target in diseases like cancer or fibrosis. Current research focuses on clarifying its mechanistic roles and validating its utility in diagnostics or targeted therapies, though most studies remain preclinical.